Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
79417.601.1471%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Eloxx Pharmaceuticals Inc

ELOXNASDAQ
Trade with Public
Trade with Public
$15.00
0.815.71%
At close: Sep 4, 5:00 PM EST
$13.96
-1.04-6.93%
After Hours: Sep 4, 7:28 AM EST
OverviewNewsEarnings ForecastPrice TargetsFinancialsSentimentOwnershipCompareStock Report

Eloxx Pharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Eloxx Pharma (ELOX).

Price Target Range — 1 Quarters

Analyst Consensus — 3 Analysts

3Buy
Consensus RatingBuy# Analysts3Avg. Consensus PT$40Upside to Avg. PT+188.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 24, 2026GuggenheimVamil DivanMaintainedBuy$43
Aug 20, 2026LUCID CAPITAL MARKETSDev Prasad InitiateBuy$38
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Guggenheim Reiterates Buy on Eloxx Pharma, Maintains $43 Price Target

Guggenheim analyst Vamil Divan reiterates Eloxx Pharma (NASDAQ:ELOX) with a Buy and maintains $43 price target.
Benzinga Newsdesk

PRO
LUCID CAPITAL MARKETS Initiates Coverage On Eloxx Pharma with Buy Rating, Announces Price Target of $38

LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Buy rating and announces Price Target of $38.
Benzinga Newsdesk

PRO
LifeSci Capital Initiates Coverage On Eloxx Pharma with Outperform Rating, Announces Price Target of $40

LifeSci Capital analyst Rami Katkhuda initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Outperform rating and announces Price Target of $40.
Benzinga Newsdesk

PRO
Guggenheim Initiates Coverage On Eloxx Pharma with Buy Rating, Announces Price Target of $43

Guggenheim analyst Vamil Divan initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Buy rating and announces Price Target of $43.
Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Eloxx Pharmaceuticals, Raises Price Target to $55

Oppenheimer analyst Hartaj Singh maintains Eloxx Pharmaceuticals (NASDAQ:ELOX) with a Outperform and raises the price target from $50 to $55.
Benzinga Newsdesk

PRO
Oppenheimer Reiterates Outperform on Eloxx Pharmaceuticals, Maintains $50 Price Target

Oppenheimer analyst Hartaj Singh reiterates Eloxx Pharmaceuticals (NASDAQ:ELOX) with a Outperform and maintains $50 price target.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved